Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
申请人:Oka Takahiro
公开号:US20070049593A1
公开(公告)日:2007-03-01
The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.